NEW YORK, March 3, 2020 /PRNewswire/ -- Spherix
Incorporated (Nasdaq: SPEX) today announced it has executed a
Scientific Research Agreement with The University of Texas Southwestern Medical Center
with the goal of using machine learning to find genetic markers in
people that indicate an increased risk of developing pancreatic
cancer.
As with many cancers, early detection is vital, but in
pancreatic cancer, surgical intervention is currently the only
effective treatment for the extension of life. Unfortunately, only
20% of individuals are diagnosed with pancreatic cancer early
enough to be surgical candidates. Reliable markers for early
detection will expand the number of patients who are eligible for
life-extending surgery.
The goal of the machine learning is to develop panels of
markers to rapidly identify patients who have initiated early
events in pancreatic cancer. Moreover, it is the goal of the
machine learning protocols to identify which individuals are at
risk for slow or rapid progression of the disease and catalyze the
development of better early detection methods. Finally, Spherix
management hopes that the machine learning approach will help
identify drugs best suited for individual patient treatment.
"We believe machine learning and artificial intelligence will be
an important part of the future of oncology drug development and
treatment," commented Anthony Hayes,
CEO of Spherix. "We hope that this machine learning will identify a
list of genetic and expression markers that reveal when aggressive
pancreatic cancer has commenced in high risk patients, which may
lead to the extension of life for these patients. As a company, we
are very excited to support this research."
About Spherix
Spherix Incorporated, a Delaware corporation (the "Company"), was
initially formed in 1967 and is currently a biotechnology company
with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest
University. Our diverse pipeline of therapeutics includes
therapies for pancreatic cancer, acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipe to treat unmet medical needs in
oncology.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its patent business contained therein. Thus,
actual results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
Spherix:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@spherix.com
|
|
www.spherix.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/spherix-executes-machine-learning-scientific-research-agreement-301015388.html
SOURCE Spherix Incorporated